According to the American Cancer Society (ACS) about one in eight American men will be diagnosed with prostate cancer in…
Exosome Diagnostics, Inc.
Exosome Diagnostics’ non-invasive, exosome-based urine test known as the ExoDx™ Prostate test, or EPI, is a commercially available risk assessment tool for detection of high-grade prostate cancer in men considering prostate biopsy. It is currently available as a laboratory
developed test (LDT) through urologists and primary care physicians in the US and Europe. The test achieved FDA Breakthrough Device designation, is included in the National Comprehensive Cancer Network (NCCN) May 2019 guidelines, received a 10-year unlimited General Services Administration (GSA) Award, and is covered by Medicare.
Exosome Diagnostics empowers the world’s leading biopharma companies’ biomarker discovery, translational research, and clinical trials through partnerships. The company offers services using RNA, cell-free DNA, and proteins with their proprietary technology to explore and
identify biomarkers. It is the first and only company that can simultaneously isolate and analyze exosomal RNA and cfDNA in a single step to achieve highest sensitivity for detecting rare mutations. Exosome Diagnostics is a core provider to support advancement of patient care.
Visit us: https://www.exosomedx.com/patients/exodx-prostate-veterans.